![Quiver Logo](/static/img/logo-icon.png)
![DYN logo](https://quiver-logos.s3.us-east-2.amazonaws.com/dyn.png)
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DYN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of DYN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DYN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to DYN
Recent picks made for DYN stock on CNBC
ETFs with the largest estimated holdings in DYN
Flights by private jets registered to DYN
![Quiver Logo](/static/img/logo-icon.png)